

2nd RAS- Targeted Drug Development Summit 2020

Date : Sep 14, 2020 - 09:00 AM - Sep 16, 05:00 PM

Event URL : <http://www.BostonEventsList.com/events/2nd-ras-targeted-drug-development-summit-2020-sep-2020>

Organizer : Hanson Wade

Venue :

Location : Hilton Boston/Woburn, 2 Forbes Rd
Woburn, MA, USA, ZIP: 01801
Phone: +16174554188

Via the latest data driven case studies from academic and industry pioneers, the 2nd RAS Targeted Drug Development Summit will shine a spotlight on optimizing the selectivity and tolerability of your anti-RAS therapies, exploring novel combination strategies and overcome translational pharmacology challenges to set the stage for the 2nd generation of mutation-targeted RAS modulating therapies yet to come.

Event stats:

42+ world class speakers, 36+ late-breaking case studies, 2 dedicated streams, 6+ technical workshops, 250 + senior attendees And 8+ hours off dedicated networking

Take advantage of our group discounts, academic rates and earlybird savings - don't miss out register now for the best rate!

URLs:

Tickets: <https://go.evvnt.com/649272-0?pid=1052>

Brochure: <https://go.evvnt.com/649272-3?pid=1052>

Prices:

Industry Pricing: 3 Day Pass - Conference + Workshop Day: USD 4696.0,

Industry Pricing: 2 Day Pass - Conference Only: USD 2899.0,

Academic Pricing: 3 Day Pass - Conference + Workshop: USD 3996.0,

Academic Pricing: 2 Day Pass - Conference Only: USD 2499.0

Speakers: Frank McCormick, Frederick National Laboratory for Cancer Research, Channing Der, University of North Carolina at Chapel Hill, Piro Lito, Memorial Sloan Kettering Center, Ryan Corcoran, Harvard Medical School, Aaron Hata, Harvard Medical School, Scott Kopetz, MD Anderson Cancer Centre, Martin McMahon, Huntsman Cancer Institute of University of Utah, Greg Beilhartz, The Hospital for Sick Children, Christine Pratilias, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Miriam Molina-Arcas, Francis Crick Institute, Jack Arbiser, Emory University School of Medicine, Benham Nabet, Dana-Farber Cancer Institute, Pan-Yu Chen, University of California, Antti Poso, University of Eastern Finland And University Hospital Tübingen, Steve Kelsey, Revolution Medicines, Peter Hammerman, Novartis, Alexander Scheer, Aelin Therapeutics, Bryan Smith, Deciphera Pharmaceuticals, Francis Burrows, Kura Oncology, Jonathan Pachter, Verastem Oncology, Erik Digman-Wiklund, Targovax, Frank Haluska, Anchiano Therapeutics, Lusong Luo, Beigene, Steven Fruchtman, Onconova Therapeutics, Mark Erlander, TrovaGene, Silvia Coma, Verastem Oncology, Jan Smith, Revolution Medicines, Sreesha Srinivasa, Oblique Therapeutics, Steven Nadler, Aro Biotherapeutics, Matt Meyer, Senior Director And Head of In Vivo Biology, Tauseef Butt, Progenra, Marco Hofmann, Boehringer Ingelheim, Nicholas Heimann, Nicholas Pharmaceuticals, Pete DeMuth, Elicio Therapeutics, Grahame McKenzie, PhoreMost, Beth Stronach, RASopathies Network, Erica Jackson, AbbVie, Marie Evangelista, Genentech, Ida Aronchik, Celgene, Yibing Shan, D.E Shaw Research, Huaixing Hao, Novartis, Richard Somberg, Promega, Kerstin Pohl, Biodesix

Event Categories :